Pharmacokinetics of Isoliquiritigenin and Its Metabolites in Rats: Low Bioavailability Is Primarily Due to the Hepatic and Intestinal Metabolism

Abstract

Isoliquiritigenin, a chalcone found in licorice has shown a variety of biological activities including antioxidative, anti-inflammatory, estrogenic, chemopreventive and antitumor effects. Thus, pharmacokinetics of isoliquiritigenin and its metabolites [liquiritigenin, glucuronidated isoliquiritigenin (M1), and glucuronidated liquiritigenin (M2)] after intravenous and oral administration of isoliquiritigenin was evaluated in rats. The pharmacokinetics of isoliquiritigenin, liquiritigenin, M1, and M2 showed no dose dependence after both intravenous and oral administration of isoliquiritigenin. Although approximately 92.0 % of the oral isoliquiritigenin was absorbed, the extent of the absolute bioavailability value was only 11.8 % of the oral dose. The low absolute bioavailability value of isoliquiritigenin might be due to the considerable metabolism of isoliquiritigenin in the small intestine and liver. This was supported by the facts that the ratios of AUC_M1/AUC_isoLQ and AUC_M2/AUC_isoLQ were high (over 0.25), isoliquiritigenin disappeared, and M1 and M2 were formed mainly in S9 fractions of the liver and small intestine. The affinities of liquiritigenin, isoliquiritigenin, M1, and M2 were high in the liver, small intestine, large intestine, and/or kidney.

Key words

Glycyrrhiza glabra - Fabaceae - isoliquiritigenin - liquiritigenin - glucuronidated metabolites - pharmacokinetics

• References

• 1 Chin YW, Jung HA, Liu Y, Su BN, Castoro JA, Keller WJ, Pereira MA, Kinghorn AD. Anti-oxidant constituents of the roots and stolons of licorice (Glycyrrhiza glabra). J Agric Food Chem 2007; 55: 4691-4697
• 2 Haraguchi H, Ishikawa H, Mizutani K, Tamura Y, Kinoshita T. Antioxidative and superoxide scavenging activities of retrochalcones in Glycyrrhiza inflata . Bioorg Med Chem 1998; 6: 339-347
• 3 Kim JY, Park SJ, Yun KJ, Cho YW, Park HJ, Lee KT. Isoliquiritigenin isolated from the roots of Glycyrrhiza uralensis inhibits LPS-induced iNOS and COX-2 expression via the attenuation of NF-kappaB in RAW 264.7 macrophages. Eur J Pharmacol 2008; 584: 175-184
• 4 Lee CK, Son SH, Park KK, Park JH, Lim SS, Chung WY. Isoliquiritigenin inhibits tumor growth and protects the kidney and liver against chemotherapy-induced toxicity in a mouse xenograft model of colon carcinoma. J Pharm Sci 2008; 106: 444-451
• 5 Baba M, Asano R, Takigami I, Takahashi T, Ohmura M, Okada Y, Sugimoto H, Arika T, Nishino H, Okuyama T. Studies on cancer chemoprevention by traditional folk medicines XXV. Inhibitory effect of isoliquiritigenin on azoxymethane-induced murine colon aberrant crypt focus formation and carcinogenesis. Biol Pharm Bull 2002; 25: 247-250
• 6 Tamir S, Eizenberg M, Somjen D, Izrael S, Vaya J. Estrogen-like activity of glabrene and other constituents isolated from licorice root. J Steroid Biochem Mol Biol 2001; 78: 291-298
• 7 Cuendet M, Oteham CP, Moon RC, Pezzuto JM. Quinone reductase induction as a biomarker for cancer chemoprevention. J Nat Prod 2006; 69: 460-463
• 8 Ross D, Kepa JK, Winski SL, Bcall HD, Anwar A, Siegel D. NAD(P)H: Quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 2000; 129: 77-97
• 9 Kim SC, Byun SH, Yang CH, Kim CY, Kim JW, Kim SG. Cytoprotective effects of Glycyrrhizae radix extract and its active component liquiritigenin against cadmium-induced toxicity (effects on bad translocation and cytochrome c-mediated PARP cleavage). Toxicology 2004; 197: 239-251
• 10 Kim YW, Ki SH, Lee JR, Lee SJ, Kim CW, Kim SC, Kim SG. Liquiritigenin, an aglycone of liquiritin in Glycyrrhizae radix, prevents acute liver injuries in rats induced by acetaminophen with or without buthionine sufoximine. Chem Biol Interact 2006; 161: 125-138
• 11 Kim YW, Zhao RJ, Park SJ, Lee JR, Cho IJ, Yang CH, Kim SG, Kim SC. Anti-inflammatory effects of liquiritigenin as a consequence of the inhibition of NF-kappaB-dependent iNOS and proinflammatory cytokines production. Br J Pharmacol 2008; 154: 165-173
• 12 Kim YW, Kang HE, Lee MG, Hwang SJ, Kim SC, Lee CH, Kim SG. Liquiritigenin, a flavonoid aglycone from licorice, has a choleretic effect and the ability to induce hepatic transporters and phase-II enzymes. Am J Physiol Gastrointest Liver Physiol 2009; 296: G372-G381
• 13 De Smet PA, Brauwers JR. Pharmacokineitc evaluation of herbal remedies: basic introduction, applicability, current status and regulatory needs. Clin Pharmacokinet 1997; 32: 427-436
• 14 Guo J, Liu A, Cao H, Luo Y, Pezzuto JM, van Breemen RB. Biotransformation of the chemopreventive agent 4,2′,4′-trihydrozychalcone (isoliguiritigenin) by UDP-glucuronosyltransferases. Drug Metab Dispos 2008; 36: 2104-2112
• 15 Guo J, Liu D, Nikolic D, Zhu D, Pezzuto JM, van Breemen RB. In vitro metabolism of isoliquiritigenin by human liver microsomes. Drug Metab Dispos 2008; 36: 461-468
• 16 Tan G, Lou Z, Dong X, Li Q, Liao W, Zhu Z, Chai Y. Urinary metabolites of isoliquiritigenin in Wistar rats using UHPLC-TOF-MS-based xenometabolomics. Chromatographia 2011; 74: 341-348
• 17 Kroemer HK, Klotz U. Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors. Clin Pharmacokinet 1992; 23: 292-310
• 18 Fromm MF, Botsch S, Keinkele G, Evers J, Kroemer HK. Influence of renal function on the steady-state pharmacokinetics of the antiarrhythmic propafenone and its phase I and phase II metabolites. Eur J Clin Pharmacol 1995; 48: 279-283
• 19 Han SY, Chin YW, Choi YH. A new approach for pharmacokinetic studies of natural products: measurement of isoliquiritigenin levels in mice plasma, urine and feces using modified automated dosing/blood sampling system. Biomed Chromatogr 2013; 27: 741-749
• 20 Shimamura H, Nakai S, Yamamoto K, Hitomi N, Yumioka E. Biliary and urinary metabolites of liquiritigenin in rat. J Pharmacogn 1990; 44: 265-268
• 21 Kang HE, Jung HJ, Cho YK, Kim SH, Sohn SI, Baek SR, Lee MG. Pharmacokinetics of liquiritigenin in mice, rats, rabbits, and dogs and animal scale-up. J Pharm Sci 2009; 98: 4327-4342
• 22 Li LH, Dong H, Zhao F, Tang J, Chen X, Ding J, Men HT, Luo WX, Du Y, Ge J, Tan BX, Cao D, Liu JY. The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil. Eur J Cancer 2013; 49: 1752-1760
• 23 Nahrstedt A, Butterweck V. Lessons learned from herbal medicinal products: the example of St. Johnʼs Wort. J Nat Prod 2010; 73: 1015-1021
• 24 Simmler C, Hajirahimkhan A, Lankin DC, Bolton JL, Jones T, Soejarto DD, Chen SN, Pauli GF. Dynamic residual complexity of the isoliquiritigenin-liquiritigenin interconversion during bioassay. J Agric Food Chem 2013; 61: 2146-2157
• 25 Davis B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1999; 10: 1093-1095
• 26 Mitruka BM, Rawnsley HM. Clinical biochemical and hematological reference values in normal experimental animals and normal humans. 2nd. edition. New York, NY: Masson Publishing USA Inc.; 1987: 113
• 27 Kang HE, Cho YK, Jung HY, Choi KY, Sohn SI, Baek SR, Lee MG. Pharmacokinetics and first-pass effects of liquiritigenin in rats: low bioavailability is primarily due to extensive gastrointestinal first-pass effect. Xenobiotica 2009; 39: 465-475
• 28 Lee MG, Chiou WL. Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm 1983; 11: 623-660
• 29 Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: drug interaction studies – study design, data analysis, implications for dosing, and labeling recommendations, U.S. Washington, DC: CDER, FDA; 2012
• 30 Choi YH, Lee U, Lee BK, Lee MG. Pharmacokinetic interaction between itraconazole and metformin in rats: competitive inhibition of metabolism of each drug by each other via hepatic and intestinal CYP3A1/2. Br J Pharmacol 2010; 161: 815-829
• 31 Choi YH, Lee U, Suh JH, Kim YG, Choi EY, Oh E, Lee MG. Pharmacokinetics and first-pass effects of epsilon-acetamidocaproic acid after administration of zinc acexamate in rats. Xenobiotica 2010; 40: 485-498
• 32 Litterst CL, Mimnaugh EG, Regan RL, Gram E. Comparison of in vitro drug metabolism by lung, liver, and kidney of several common laboratory species. Drug Metab Dispos 1975; 3: 259-265
• 33 Chiou WL. New calculation method of mean apparent drug volume of distribution and application to rational dosage regimen. J Pharm Sci 1979; 68: 1067-1069
• 34 Gibaldi M, Perrier D. Pharmacokinetics. 2nd. edition. New York, NY: Marcel-Dekker; 1982
• 35 Kim SH, Choi YM, Lee MG. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 1993; 21: 1-17